$REED
REED'S, INC. Stock $reed

$reed Overview Financials Valuation SEC Filings Company Website

2024 Q2 Form 10-Q Financial Statement

#000149315224020661 Filed on May 20, 2024

Income Statement

Concept	2024 Q2	2024 Q1	2023 Q1
Revenue	$11.87M	$9.595M	$11.16M
YoY Change	18.68%	-14.0%	-8.41%
Cost Of Revenue	$8.043M	$6.182M	$8.459M
YoY Change	7.3%	-26.92%	-8.55%
Gross Profit	$3.831M	$3.413M	$2.698M
YoY Change	52.69%	26.5%	-7.98%
Gross Profit Margin	32.26%	35.57%	24.18%
Selling, General & Admin	$3.077M	$2.561M	$3.156M
YoY Change	19.73%	-18.85%	-26.59%
% of Gross Profit	80.32%	75.04%	116.98%
Research & Development
YoY Change
% of Gross Profit
Depreciation & Amortization		$29.00K	$47.00K
YoY Change		-38.3%	88.0%
% of Gross Profit		0.85%	1.74%
Operating Expenses	$4.500M	$4.063M	$5.276M
YoY Change	5.73%	-22.99%	-25.81%
Operating Profit	-$669.0K	-$650.0K	-$2.578M
YoY Change	-61.71%	-74.79%	-38.31%
Interest Expense	$1.150M	$1.023M	$1.779M
YoY Change	-17.09%	-42.5%	-322.1%
% of Operating Profit
Other Income/Expense, Net
YoY Change
Pretax Income		-$1.673M	-$4.357M
YoY Change		-61.6%	-12.51%
Income Tax
% Of Pretax Income
Net Earnings	-$3.212M	-$1.673M	-$4.357M
YoY Change	2.49%	-61.6%	-12.51%
Net Earnings / Revenue	-27.05%	-17.44%	-39.05%
Basic Earnings Per Share	-$0.77	-$0.40	-$1.70
Diluted Earnings Per Share	-$0.77	-$0.40	-$1.70
COMMON SHARES
Basic Shares Outstanding	4.187M shares	4.187M shares	2.602M shares
Diluted Shares Outstanding	4.187M shares	4.187M shares	2.560M shares

Balance Sheet

Concept	2024 Q2	2024 Q1	2023 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$4.526M	$314.0K	$467.0K
YoY Change	912.53%	-32.76%	282.79%
Cash & Equivalents	$326.0K	$314.0K	$467.0K
Short-Term Investments	$4.200M
Other Short-Term Assets		$2.332M	$601.0K
YoY Change		288.02%	-61.5%
Inventory	$10.22M	$12.02M	$15.30M
Prepaid Expenses
Receivables	$5.297M	$3.251M	$4.665M
Other Receivables		$264.0K	$777.0K
Total Short-Term Assets	$17.73M	$18.18M	$21.81M
YoY Change	-9.23%	-16.66%	-24.34%
LONG-TERM ASSETS
Property, Plant & Equipment	$384.0K	$441.0K	$686.0K
YoY Change	-29.28%	-35.71%	-27.02%
Goodwill
YoY Change
Intangibles	$694.0K	$686.0K	$676.0K
YoY Change	2.36%	1.48%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$1.019M	$1.072M	$1.312M
YoY Change	-12.91%	-18.29%	-16.11%
TOTAL ASSETS
Total Short-Term Assets	$17.73M	$18.18M	$21.81M
Total Long-Term Assets	$1.019M	$1.072M	$1.312M
Total Assets	$18.75M	$19.25M	$23.12M
YoY Change	-9.44%	-16.75%	-23.91%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$8.432M	$8.484M	$11.17M
YoY Change	17.09%	-24.01%	-31.75%
Accrued Expenses	$946.0K	$872.0K	$467.0K
YoY Change	18.55%	86.72%	-45.44%
Deferred Revenue
YoY Change
Short-Term Debt		$7.844M	$7.593M
YoY Change		3.31%	1.58%
Long-Term Debt Due		$7.339M	$5.485M
YoY Change		33.8%
Total Short-Term Liabilities	$37.10M	$25.03M	$26.76M
YoY Change	60.53%	-6.49%	5.26%
LONG-TERM LIABILITIES
Long-Term Debt		$10.85M	$8.526M
YoY Change		27.29%
Other Long-Term Liabilities		$4.097M	$156.0K
YoY Change		2526.28%	-55.43%
Total Long-Term Liabilities		$14.95M	$8.682M
YoY Change		72.2%	2380.57%
TOTAL LIABILITIES
Total Short-Term Liabilities	$37.10M	$25.03M	$26.76M
Total Long-Term Liabilities		$14.95M	$8.682M
Total Liabilities	$42.59M	$39.98M	$35.45M
YoY Change	32.44%	12.78%	37.52%
SHAREHOLDERS EQUITY
Retained Earnings	-$143.6M	-$140.4M	-$127.6M
YoY Change	9.89%	10.07%
Common Stock	$0.00	$0.00	$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$23.85M	-$20.73M	-$12.32M
YoY Change
Total Liabilities & Shareholders Equity	$18.75M	$19.25M	$23.12M
YoY Change	-9.44%	-16.75%	-23.91%

Cashflow Statement

Concept	2024 Q2	2024 Q1	2023 Q1
OPERATING ACTIVITIES
Net Income	-$3.212M	-$1.673M	-$4.357M
YoY Change	2.49%	-61.6%	-12.51%
Depreciation, Depletion And Amortization		$29.00K	$47.00K
YoY Change		-38.3%	88.0%
Cash From Operating Activities		-$2.395M	$1.117M
YoY Change		-314.41%	-150.61%
INVESTING ACTIVITIES
Capital Expenditures		$16.00K
YoY Change
Acquisitions
YoY Change
Other Investing Activities			$0.00
YoY Change
Cash From Investing Activities		-$18.00K
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities		$2.124M	-$1.183M
YoY Change		-279.54%	-151.89%
NET CHANGE
Cash From Operating Activities		-$2.395M	$1.117M
Cash From Investing Activities		-$18.00K
Cash From Financing Activities		$2.124M	-$1.183M
Net Change In Cash		-$289.0K	-$66.00K
YoY Change		337.88%
FREE CASH FLOW
Cash From Operating Activities		-$2.395M	$1.117M
Capital Expenditures		$16.00K
Free Cash Flow		-$2.411M	$1.117M
YoY Change		-315.85%	-150.61%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2024Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2024Q1	dei	Entity File Number EntityFileNumber	001-32501
CY2024Q1	dei	Entity Registrant Name EntityRegistrantName	REED’S, INC.
CY2024Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2024Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	35-2177773
CY2024Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	201 Merritt 7
CY2024Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Norwalk
CY2024Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CT
CY2024Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	06851
CY2024Q1	dei	City Area Code CityAreaCode	(800)
CY2024Q1	dei	Local Phone Number LocalPhoneNumber	997-3337
CY2023Q4	REED	Safe Agreements SAFEAgreements		usd
CY2024Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2024Q1	REED	Fair Value Of Vested Restricted Shares Granted To Officers FairValueOfVestedRestrictedSharesGrantedToOfficers		usd
CY2023Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets		usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2024Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2023Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity		usd
CY2024Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock		usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeited In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeitedInPeriod		shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Forfeitures Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsForfeituresWeightedAverageGrantDateFairValue
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue		usd
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1		usd
CY2023	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction		usd
CY2024Q1	dei	Document Type DocumentType	10-Q
CY2024Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2024Q1	dei	Document Period End Date DocumentPeriodEndDate	2024-03-31
CY2024Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2024
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4187291	shares
CY2024Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2024Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2024Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2024Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2024Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2024Q1	dei	Entity Shell Company EntityShellCompany	false
CY2024Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	4187291	shares
CY2024Q1	us-gaap	Cash Cash	314000	usd
CY2023Q4	us-gaap	Cash Cash	603000	usd
CY2023Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	860000	usd
CY2024Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3251000	usd
CY2023Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	3571000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	12017000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11300000	usd
CY2024Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2332000	usd
CY2023Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2028000	usd
CY2024Q1	us-gaap	Assets Current AssetsCurrent	18178000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	17761000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1068000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	441000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	493000	usd
CY2024Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	631000	usd
CY2023Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	629000	usd
CY2024Q1	us-gaap	Assets Assets	19250000	usd
CY2023Q4	us-gaap	Assets Assets	18883000	usd
CY2024Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	8484000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	9133000	usd
CY2024Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	872000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1096000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	201000	usd
CY2024Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	7844000	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	9758000	usd
CY2024Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	7339000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	6737000	usd
CY2024Q1	REED	Safe Agreements SAFEAgreements	4097000	usd
CY2024Q1	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	10853000	usd
CY2023Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	8459000	usd
CY2024Q1	REED	Delivery And Handling Expense DeliveryAndHandlingExpense	1502000	usd
CY2023Q1	REED	Delivery And Handling Expense DeliveryAndHandlingExpense	2120000	usd
CY2024Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1093000	usd
CY2023Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1447000	usd
CY2024Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1468000	usd
CY2023Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1709000	usd
CY2024Q1	us-gaap	Operating Expenses OperatingExpenses	4063000	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	5276000	usd
CY2024Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-650000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2578000	usd
CY2024Q1	us-gaap	Interest Expense InterestExpense	1023000	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	1779000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1673000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4357000	usd
CY2024Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.40
CY2024Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.40
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.70
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.70
CY2024Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	4187291	shares
CY2024Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	4187291	shares
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	2559855	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	2559855	shares
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-19181000	usd
CY2024Q1	REED	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Vested AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsVested	129000	usd
CY2024Q1	us-gaap	Net Income Loss NetIncomeLoss	-1673000	usd
CY2024Q1	us-gaap	Stockholders Equity StockholdersEquity	-20725000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-8470000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	4000	usd
CY2023Q1	us-gaap	Stock Repurchased During Period Value StockRepurchasedDuringPeriodValue	1000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	273000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4357000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-12322000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	-12322000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-4357000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	29000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	47000	usd
CY2024Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	144000	usd
CY2023Q1	us-gaap	Amortization Of Debt Discount Premium AmortizationOfDebtDiscountPremium	281000	usd
CY2024Q1	REED	Fair Value Of Vested Options FairValueOfVestedOptions	129000	usd
CY2023Q1	REED	Fair Value Of Vested Options FairValueOfVestedOptions	229000	usd
CY2023Q1	REED	Fair Value Of Vested Restricted Shares Granted To Officers FairValueOfVestedRestrictedSharesGrantedToOfficers	-4000	usd
CY2024Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-601000	usd
CY2023Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	-39000	usd
CY2024Q1	us-gaap	Inventory Write Down InventoryWriteDown	-783000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	-228000	usd
CY2024Q1	REED	Accrual Of Interest On Convertible Note AccrualOfInterestOnConvertibleNote	564000	usd
CY2023Q1	REED	Accrual Of Interest On Convertible Note AccrualOfInterestOnConvertibleNote	1113000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-922000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1044000	usd
CY2024Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-66000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-1102000	usd
CY2024Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	1305000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-338000	usd
CY2024Q1	REED	Increase Decrease In Amortization Of Right Of Use Assets IncreaseDecreaseInAmortizationOfRightOfUseAssets	-39000	usd
CY2023Q1	REED	Increase Decrease In Amortization Of Right Of Use Assets IncreaseDecreaseInAmortizationOfRightOfUseAssets	-32000	usd
CY2024Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	351000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1360000	usd
CY2024Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-225000	usd
CY2023Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	235000	usd
CY2024Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-52000	usd
CY2023Q1	us-gaap	Increase Decrease In Operating Lease Liability IncreaseDecreaseInOperatingLeaseLiability	-44000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-2395000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	1117000	usd
CY2024Q1	us-gaap	Payments To Acquire Intangible Assets PaymentsToAcquireIntangibleAssets	2000	usd
CY2024Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	16000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-18000	usd
CY2024Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	8285000	usd
CY2023Q1	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	8699000	usd
CY2024Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	10239000	usd
CY2023Q1	us-gaap	Repayments Of Lines Of Credit RepaymentsOfLinesOfCredit	12120000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	2405000	usd
CY2024Q1	us-gaap	Proceeds From Issuance Or Sale Of Equity ProceedsFromIssuanceOrSaleOfEquity	4097000	usd
CY2024Q1	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	86000	usd
CY2023Q1	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	1000	usd
CY2024Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	67000	usd
CY2023Q1	us-gaap	Proceeds From Repayments Of Related Party Debt ProceedsFromRepaymentsOfRelatedPartyDebt	-166000	usd
CY2024Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	2124000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1183000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-289000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-66000	usd
CY2023Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	603000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	533000	usd
CY2024Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	314000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations	467000	usd
CY2024Q1	us-gaap	Interest Paid Net InterestPaidNet	318000	usd
CY2023Q1	us-gaap	Interest Paid Net InterestPaidNet	390000	usd
CY2024Q1	REED	Reclass Of Prepaid Expenses And Accounts Payable ReclassOfPrepaidExpensesAndAccountsPayable	1000000	usd
CY2023Q1	REED	Reclass Of Prepaid Expenses And Accounts Payable ReclassOfPrepaidExpensesAndAccountsPayable	0	usd
CY2024Q1	us-gaap	Cash Cash	314000	usd
CY2024Q1	REED	Additional Cash Received AdditionalCashReceived	4100000	usd
CY2024Q1	REED	Carrying Cost Property And Exploration Rights CarryingCostPropertyAndExplorationRights	3.01	pure
CY2023Q1	REED	Carrying Cost Property And Exploration Rights CarryingCostPropertyAndExplorationRights	3.46	pure
CY2024Q1	us-gaap	Advertising Expense AdvertisingExpense	17000	usd
CY2023Q1	us-gaap	Advertising Expense AdvertisingExpense	55000	usd
CY2024Q1	us-gaap	Use Of Estimates UseOfEstimates	<p id="xdx_846_eus-gaap--UseOfEstimates_ztkivor19jJh" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_863_zOnhrrQcrUX8">Use of Estimates</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, disclosures of contingent assets and liabilities at the date of the financial statements, and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Those estimates and assumptions include estimates for credit loss reserves for accounts receivable, assumptions used in valuing inventories at net realizable value, impairment testing of recorded long-term tangible and intangible assets, the valuation allowance for deferred tax assets, accruals for potential liabilities, assumptions made in valuing stock instruments issued for services, and assumptions used in the determination of the Company’s liquidity.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	2248980000	shares
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1669360000	shares
CY2024Q1	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p id="xdx_84F_eus-gaap--ConcentrationRiskCreditRisk_zswVdQmu5Urd" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b><span id="xdx_86E_zwTXyRJPpu53">Concentrations</span></b></span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Net sales.</i> During the three months ended March 31, 2024, the Company’s two largest customers accounted for <span id="xdx_906_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z8zgCa2p4Pti" title="Concentration risk percentage">17</span>% and <span id="xdx_90D_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z14OHfcuIc4b" title="Concentration risk percentage">16</span>% of net sales, respectively. During the three months ended March 31, 2023, the Company’s two largest customers accounted for <span id="xdx_90E_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zgRrjTr6hjl7" title="Concentration risk percentage">18</span>% and <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zhyj2oMUPqL1" title="Concentration risk percentage">12</span>% of net sales, respectively. No other customers exceeded 10% of net sales in either period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts receivable.</i> As of March 31, 2024, the Company had accounts receivable from one customer which comprised <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20240101__20240331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z6mZd5nQTry6" title="Concentration risk, percentage">29</span>% of its gross accounts receivable. As of December 31, 2023, the Company had accounts receivable from three customers which comprised <span id="xdx_90A_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zi0ugSeplv9c" title="Concentration risk, percentage">24</span>%, <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z7lvzM1EIYg3" title="Concentration risk, percentage">15</span>% and <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_uPure_c20230101__20230331__srt--MajorCustomersAxis__custom--CustomerThreeMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsReceivableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zUrFNZe1vIhk" title="Concentration risk, percentage">11</span>% of its gross accounts receivable, respectively. No other customers exceeded 10% of gross accounts receivable in either period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>The Company utilizes co-packers to produce 100% of its products.</i> During the three months ended March 31, 2024 and the year ended December 31, 2023, the Company utilized six separate co-packers for most its production and bottling of beverage products in the United States. The Company has long-standing relationships with two different co-packers, and a third co-packing agreement with California Custom Beverage LLC (“CCB”), a former related party (see Note 11). Although there are other packers, a change in co-packers may cause a delay in the production process, which could ultimately affect operating results.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Purchases from vendors.</i> During the three months ended March 31, 2024, the Company’s largest vendor accounted for approximately <span id="xdx_907_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_zYIHqtySaJO6">10</span>% of all purchases. During the three months ended March 31, 2023, the Company’s largest vendor accounted for approximately <span id="xdx_908_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--SalesRevenueNetMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--ProductConcentrationRiskMember_z6ZvABWhdEla">11</span>% of all purchases. No other vendors exceeded 10% of all purchases in either period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><i>Accounts payable.</i> As of March 31, 2024, one vendor accounted for <span id="xdx_902_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20240101__20240331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_zxCT777uxZq9">11</span>% of total accounts payable. As of December 31, 2023, two vendors accounted for <span id="xdx_909_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorOneMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z91rESf8l7ll">10</span>% and <span id="xdx_90C_eus-gaap--ConcentrationRiskPercentage1_pid_dp_c20230101__20230331__srt--MajorCustomersAxis__custom--VendorTwoMember__us-gaap--ConcentrationRiskByBenchmarkAxis__us-gaap--AccountsPayableMember__us-gaap--ConcentrationRiskByTypeAxis__us-gaap--CustomerConcentrationRiskMember_z9JO5jZtlb8">10</span>% of total accounts payable, respectively. No other vendors exceeded 10% of accounts payable in either period.</span></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Prior Period Reclassification Adjustment Description PriorPeriodReclassificationAdjustmentDescription	<p id="xdx_840_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_z5AvDP1rYfSl" style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: left"><b>Reclassifications</b></p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; background-color: white"> </p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">Certain prior year amounts have been reclassified for consistency with the current period presentation. Collection from customers amounting to $<span id="xdx_909_eus-gaap--ProceedsFromCustomers_pn3n3_c20240101__20240331_zD4bHVAQlGu3" title="Collection from customers">1,217</span> that was previously presented as a deduction from prepaid expenses have been reclassed as an offset against accounts receivable. These reclassifications had no effect on the reported results of operations or cash flows.</p> <p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"> </span></p>
CY2024Q1	us-gaap	Proceeds From Customers ProceedsFromCustomers	1217000	usd
CY2024Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	6766000	usd
CY2023Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	6445000	usd
CY2024Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	5251000	usd
CY2023Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	4855000	usd
CY2024Q1	us-gaap	Inventory Net InventoryNet	12017000	usd
CY2023Q4	us-gaap	Inventory Net InventoryNet	11300000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1577000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	1561000	usd
CY2024Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1136000	usd
CY2023Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1068000	usd
CY2024Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	441000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	493000	usd
CY2024Q1	us-gaap	Depreciation Depreciation	29000	usd
CY2023Q1	us-gaap	Depreciation Depreciation	47000	usd
CY2024Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	39000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset Amortization Expense OperatingLeaseRightOfUseAssetAmortizationExpense	32000	usd
CY2024Q1	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	576000	usd
CY2023Q4	us-gaap	Indefinite Lived Trade Names IndefiniteLivedTradeNames	576000	usd
CY2024Q1	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	55000	usd
CY2023Q4	us-gaap	Indefinite Lived Trademarks IndefiniteLivedTrademarks	53000	usd
CY2024Q1	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	631000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	629000	usd
CY2024Q1	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	161000	usd
CY2023Q4	us-gaap	Deferred Finance Costs Current Net DeferredFinanceCostsCurrentNet	201000	usd
CY2024Q1	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	7844000	usd
CY2023Q4	us-gaap	Lines Of Credit Current LinesOfCreditCurrent	9758000	usd
CY2022Q3	us-gaap	Line Of Credit Facility Unused Capacity Commitment Fee Percentage LineOfCreditFacilityUnusedCapacityCommitmentFeePercentage	0.10	pure
CY2022Q3	us-gaap	Proceeds From Lines Of Credit ProceedsFromLinesOfCredit	6000000	usd
CY2023Q2	us-gaap	Debt Issuance Costs Line Of Credit Arrangements Net DebtIssuanceCostsLineOfCreditArrangementsNet	7500000	usd
CY2024Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10250000	usd
CY2023Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	10250000	usd
CY2024Q1	us-gaap	Lease Cost LeaseCost	39000	usd
CY2023Q1	us-gaap	Lease Cost LeaseCost	32000	usd
CY2023Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	207000	usd
CY2024Q1	us-gaap	Operating Lease Payments OperatingLeasePayments	52000	usd
CY2024Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	155000	usd
CY2024Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P0Y9M
CY2024Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.1260	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	145012	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	45.09
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y9M
CY2024Q1	REED	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedForfeituresAndExpirationsInPeriod	-3143	shares
CY2024Q1	REED	Share Based Compensation Arrangement By Share Based Payment Award Options Vested Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	45.05
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	141869	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	44.03
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P6Y6M
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	111583	shares
CY2024Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	51.09
CY2024Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P6Y25D
CY2024Q1	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	264000	usd
CY2023	us-gaap	Proceeds From Related Party Debt ProceedsFromRelatedPartyDebt	259000	usd
CY2024Q1	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	331000	usd
CY2023	us-gaap	Repayments Of Related Party Debt RepaymentsOfRelatedPartyDebt	259000	usd
CY2024Q1	us-gaap	Related Party Transaction Amounts Of Transaction RelatedPartyTransactionAmountsOfTransaction	-67000	usd

Files In Submission

Name	View Source	Status
reed-20240331_def.xml	Edgar Link	unprocessable
0001493152-24-020661-index-headers.html	Edgar Link	pending
0001493152-24-020661-index.html	Edgar Link	pending
0001493152-24-020661.txt	Edgar Link	pending
0001493152-24-020661-xbrl.zip	Edgar Link	pending
ex10-3.htm	Edgar Link	pending
ex31.htm	Edgar Link	pending
ex32.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
form10-q.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
form10-q_htm.xml	Edgar Link	completed
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
reed-20240331.xsd	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
reed-20240331_cal.xml	Edgar Link	unprocessable
reed-20240331_pre.xml	Edgar Link	unprocessable
reed-20240331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$REED
REED'S, INC. Stock $reed

2024 Q2 Form 10-Q Financial Statement

#000149315224020661 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REED REED'S, INC. Stock $reed

2024 Q2 Form 10-Q Financial Statement

#000149315224020661 Filed on May 20, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$REED
REED'S, INC. Stock $reed